This is part of the issue for me, and my major question on Tuesday.
LDX keep referencing Hologic charge $64.41 USD per fFN test.
LDX never tell shareholders if we will get lifetime royalties and if so - what %.
We could have fingers in 16 different pies, or none.
If LDX actually laid out in black and white our potential revenue - even if only by percentage - there would be a rerate of the SP.
Ann: Lumos Achieves First Phase 2 Milestone in Hologic Agreement, page-4
Add to My Watchlist
What is My Watchlist?
